This study explored the resistance mechanisms of Staphylococcus aureus (S. aureus) to novobiocin, a gyrB inhibitor. Through adaptive laboratory evolution, key resistance mutations (in gyrB, potB, and ...

As the first clinical trial of the drug novobiocin is about to open for patients with cancers carrying BRCA gene mutations, new research at Dana-Farber Cancer Institute shows the drug poses a double ...

The present report deals with the in vitro anti-microbial activity of novobiocin and its efficacy in the treatment of a variety of surgical infections due to staphylococci and other gram-positive ...

Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. Resistance to alkylators may potentially be overcome by drugs that inhibits DNA repair, thus ...

Dana-Farber Cancer Institute scientists have discovered that an antibiotic developed in the 1950s and largely superseded by newer drugs, effectively targets and kills cancer cells that have a common ...

BOSTON - An antibiotic developed in the 1950s and largely supplanted by newer drugs, effectively targets and kills cancer cells with a common genetic defect, laboratory research by Dana-Farber Cancer ...

THE clinical use of novobiocin is increasing because of its effectiveness in the treatment of staphylococcal infections. Toxic reactions 1, 2 include mild diarrhea (37 per cent), skin rashes (8.9 per ...

After a landmark clinical trial of the first POLQ inhibitor in cancer last year, a recently formed U.K. biotech is gearing up to bring a potential rival to the clinic in the coming months. Varsity ...

An antibiotic developed in the 1950s and largely supplanted by newer drugs, effectively targets and kills cancer cells with a common genetic defect, laboratory research by Dana-Farber Cancer Institute ...

CAMBRIDGE, England--(BUSINESS WIRE)--Varsity Pharmaceuticals (Varsity), a biopharmaceutical company developing small molecule therapies that target treatment resistant cancers, today announced that it ...